Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2586881 in Pulmonary Arterial Hypertension
NCT03177603Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2018
- Primary completion
- May 2019
- Modality
- Peptides, Replacement Enzymes
- Countries
- 3
01
Overview
Phase 2, open-label trial of alunacedase alfa in pulmonary arterial hypertension (PAH) (4 cohorts), sponsored by GSK. Primary endpoints: Change From Baseline in Pulmonary Vascular Resistance at 4 hours, Change From Baseline in Cardiac Output at 4 hours and 1 more. Started Feb 2018; status: completed.
02
Drugs
alunacedase alfa
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03177603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03177603.